How do I interpret the C‑peptide‑to‑glucose ratio (CGR) and use it to guide therapy in an adult with type 2 diabetes?

How to Interpret and Use C-Peptide-to-Glucose Ratio (CGR) in Type 2 Diabetes

Measure fasting C-peptide when simultaneous fasting plasma glucose is ≤220 mg/dL (12.5 mmol/L), and use the C-peptide-to-glucose ratio (CGR) to determine insulin secretory capacity: a CGR <1.62 indicates severe insulin deficiency requiring immediate insulin therapy, while a CGR >3.11 suggests preserved beta cell function allowing for non-insulin therapies. 1, 2

Understanding CGR Values and Clinical Thresholds

The CGR provides a practical estimate of pancreatic beta cell function by normalizing C-peptide levels to concurrent glucose concentrations. This ratio discriminates between insulin deficiency and preserved insulin secretion, which is essential for selecting appropriate glucose-lowering medications 2.

Key CGR Cutoff Values:

• CGR <1.62: Indicates severe insulin deficiency with 90.7% specificity for predicting future insulin requirement 3
• CGR 1.62-3.11: Intermediate beta cell function requiring individualized assessment
• CGR >3.11: Preserved beta cell function with 90.1% sensitivity for low likelihood of needing insulin therapy 3

For absolute C-peptide values, the 2023 ADA/EASD guidelines provide additional context: C-peptide <0.2 nmol/L (<0.6 ng/mL) suggests type 1 diabetes or severe insulin deficiency, while C-peptide >0.6 nmol/L (>1.8 ng/mL) indicates type 2 diabetes with preserved beta cell function 1, 4.

Three-Step Algorithm for Using CGR to Guide Therapy

Step 1: Detect Severe Insulin Deficiency (CGR <1.62)

Immediate action required: Initiate insulin therapy regardless of other glucose-lowering medications 2. These patients have insufficient beta cell reserve to respond adequately to non-insulin therapies. This aligns with ADA recommendations to initiate insulin when there is evidence of ongoing catabolism, unexpected weight loss, or very high glucose levels (A1C >10% or glucose ≥300 mg/dL) 5.

Step 2: Assess Cardiovascular and Renal Risk (CGR 1.62-3.11 or higher)

For patients with preserved beta cell function (higher CGR), prioritize medications based on comorbidities rather than glucose-lowering alone:

• If heart failure present: Add SGLT2 inhibitor for prevention of HF hospitalizations 5
• If CKD present (eGFR 20-60 mL/min/1.73m² or albuminuria): Add SGLT2 inhibitor to minimize CKD progression and reduce cardiovascular events 5
• If established ASCVD or high cardiovascular risk: Add GLP-1 RA or SGLT2 inhibitor with proven cardiovascular benefit 5, 6

Strong recommendation: Add SGLT2 inhibitor or GLP-1 RA to metformin when CGR indicates preserved beta cell function, as these reduce all-cause mortality and major adverse cardiovascular events 6. Do NOT add DPP-4 inhibitors, as they do not reduce mortality or major cardiovascular events despite glucose-lowering effects 6.

Step 3: Consider De-escalation in Mild Phenotypes (CGR >3.11)

Patients with high CGR and mild hyperglycemia may be candidates for therapy de-escalation 2. Reassess the need for sulfonylureas or insulin, which carry higher hypoglycemia risk, particularly if glucose control is adequate on other agents 5.

Practical Testing Considerations

When to Measure C-Peptide:

• Timing: Fasting sample when fasting glucose ≤220 mg/dL (12.5 mmol/L) 1
• Alternative: Random C-peptide with concurrent glucose within 5 hours of eating can replace formal stimulation testing if result is >600 pmol/L (>1.8 ng/mL) 4
• Avoid testing: Within 2 weeks of hyperglycemic emergency or diabetic ketoacidosis 4
• Only test: In patients receiving insulin treatment or when diabetes classification is ambiguous 1

Important Caveats:

Assay variability is a major limitation: C-peptide measurements lack standardization across laboratories, with significant variability between manufacturers 7. Results from different assays may not be directly comparable, which can affect clinical decisions when using specific cutoff values. Always use the same laboratory for serial measurements.

Insulin resistance confounds interpretation: In type 2 diabetes with significant insulin resistance, C-peptide levels may be elevated despite relative beta cell dysfunction 8, 9. The CGR partially accounts for this by normalizing to glucose, but interpretation should consider clinical context including BMI, presence of acanthosis nigricans, and metabolic syndrome features 1.

Postprandial CGR may be more informative: The 1-hour post-glucose load C-peptide-to-glucose ratio shows the highest correlation with maximal beta cell secretory capacity (r=0.879) and disposition index (r=0.647), with superior diagnostic accuracy for diabetes (AUC 0.937) compared to fasting measurements 10. However, fasting CGR remains more practical for routine clinical use 2.

Integration with Current Treatment Guidelines

The CGR-guided approach complements rather than replaces current guideline recommendations. For newly diagnosed type 2 diabetes with A1C ≥7.5%, early combination therapy should still be considered, typically metformin plus a second agent 11. However, CGR helps determine whether that second agent should be insulin (if CGR <1.62) or a GLP-1 RA/SGLT2 inhibitor (if CGR preserved) 2.

For patients with A1C >9% or symptomatic hyperglycemia, measure CGR to distinguish those requiring immediate insulin (low CGR) from those who may respond to intensive non-insulin combination therapy (preserved CGR) 5, 2.

Do not routinely measure insulin or proinsulin for clinical decision-making, as these assays are primarily useful for research purposes and do not provide additional clinical benefit over C-peptide measurement 1.